A new standard of care for treatment of ovarian cancer
- 1 January 2000
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 36 (1) , 10-12
- https://doi.org/10.1016/s0959-8049(99)00210-5
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidenceBritish Journal of Cancer, 1998
- Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinomaAnnals of Oncology, 1998
- Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.Journal of Clinical Oncology, 1997
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- Carboplatin versus cisplatinAnnals of Oncology, 1993
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989